- Home
- ADAP vs CHRS Comparison
ADAP vs CHRS Comparison
Compare ADAP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- CHRS
- Stock Information
- Founded
- ADAP 2008
- CHRS 2010
- Country
- ADAP United Kingdom
- CHRS United States
- Employees
- ADAP N/A
- CHRS N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADAP Health Care
- CHRS Health Care
- Exchange
- ADAP Nasdaq
- CHRS Nasdaq
- Market Cap
- ADAP 212.3M
- CHRS 185.5M
- IPO Year
- ADAP 2015
- CHRS 2014
- Fundamental
- Price
- ADAP $0.62
- CHRS $1.65
- Analyst Decision
- ADAP Strong Buy
- CHRS Strong Buy
- Analyst Count
- ADAP 4
- CHRS 4
- Target Price
- ADAP $2.79
- CHRS $5.38
- AVG Volume (30 Days)
- ADAP 2.3M
- CHRS 10.3M
- Earning Date
- ADAP 11-13-2024
- CHRS 11-06-2024
- Dividend Yield
- ADAP N/A
- CHRS N/A
- EPS Growth
- ADAP N/A
- CHRS N/A
- EPS
- ADAP N/A
- CHRS N/A
- Revenue
- ADAP $175,041,000.00
- CHRS $304,340,000.00
- Revenue This Year
- ADAP $204.91
- CHRS $1.64
- Revenue Next Year
- ADAP N/A
- CHRS $16.98
- P/E Ratio
- ADAP N/A
- CHRS N/A
- Revenue Growth
- ADAP 146.27
- CHRS 44.19
- 52 Week Low
- ADAP $0.43
- CHRS $0.66
- 52 Week High
- ADAP $2.05
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- ADAP 37.29
- CHRS 67.08
- Support Level
- ADAP $0.57
- CHRS $1.45
- Resistance Level
- ADAP $0.61
- CHRS $1.85
- Average True Range (ATR)
- ADAP 0.04
- CHRS 0.22
- MACD
- ADAP -0.00
- CHRS 0.01
- Stochastic Oscillator
- ADAP 27.46
- CHRS 42.21
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.